BeyondSpring, Inc. · NASDAQ:BYSI
BeyondSpring — Investor Day (June 2021)
90 slides from BeyondSpring's investor day presentation, Jun 25, 2021
Slide 1: Plinabulin R&D Day
Plinabulin R&D Day June 25, 2021 | NASDAQ: BYSI 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared for informational purposes only. No money or other consideration is being solicited, and if sent in response, will not be accepted. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shal
Slide 3: Agenda
Agenda 1. Introduction Dr. Lan Huang, CEO 2. Overview Triple IO Strategy with Plinabulin Dr. Ramon Mohanlal, CMO, EVP R&D 3. Plinabulin + Nivolumab + Ipilimumab Dr. Ramon Mohanlal, CMO, EVP R&D 4. Plinabulin + Radiotherapy + PD1/PD-L1-inhibitor Dr. Steven Lin, MD Anderson 5. DUBLIN-3 Dr. Trevor Fein
Slide 4: Leading Expert Speakers Biographies
Leading Expert Speakers Biographies Dr. Steven Lin is an Associate Professor and Physician Scientist at MD Anderson Cancer Center, with joint appointments in the Departments of Radiation Oncology and Experimental Radiation Oncology. Dr. Lin’s practice focuses on thoracic malignancies, and he oversee
Slide 5: Dr. Lan Huang, CEO and Co-Founder: Introduction
Dr. Lan Huang, CEO and Co-Founder Introduction 5
Slide 6: Two Near-Term NDAs & Robust Drug Development Pipeline
Two Near-Term NDAs & Robust Drug Development Pipeline Indication / Trial Name / Commercial Program Preclinical Phase 1 Phase 2 Phase 3 Status/Next Milestone Target Collaborator Rights1 CIN PROTECTIVE-1 China and U.S. NDA submission in March (All cancer, all Plinabulin + pegfilgrastim Phase 3 primary
Slide 7: Plinabulin Value Generation Roadmap
Plinabulin Value Generation Roadmap Proven Expand Transform Promising early clinical efficacy data Phase 3 study fully enrolled (n=559) – Jun. 2021 (ASCO) & Expected in 2022 & Topline OS data - mid-2021 Proven in 6 clinical studies(n>1200) & Filed for NDA approval – Mar. 2021 CIN (BTD) NSCLC Multipl
Slide 8: Plinabulin: "Pipeline in a Drug"
Plinabulin: “Pipeline in a Drug” First-in-Class, Selective Immunomodulating Microtubule-Binding Agent (SIMBA) 8
Slide 9: Building the Plinabulin Franchise
Building the Plinabulin Franchise Anti-Cancer IO Anti-Cancer 1st Line CIN Proof of Concept Extension Raise the Standard of DUBLIN-3 in NSCLC Expand to 1st Line in Care Big Ten in SCLC ‘all’ cancers and in ‘all’ MD Anderson Basket triple combinations 9
Slide 10: CIN is a Problem with Bone Marrow, Independent of Chemotherapy and Cancer
CIN is a Problem with Bone Marrow, Independent of Chemotherapy and Cancer The Premise • Chemotherapy kills fast dividing cells, which includes cancer cells, and white blood cells in bone marrow • CIN is a problem with bone marrow, and not a problem with a specific type of cancer • All G-CSF and bios
Slide 11: Favorable Benefit/Risk Ratio (Plinabulin + G-CSF vs. G-CSF alone)
Favorable Benefit/Risk Ratio (Plinabulin + G-CSF vs. G-CSF alone) Improved Efficacy (ANC based Improved Efficacy (FN) Favorable Safety in Cycle 1) – 106 Phase 3 – 106 Phase 3 – 106 Phase 2+3 No Grade 4 Neutropenia FN Grade 4 TEAE • 31.5% vs. 13.6% (incidence), p=0.0015 • 3.6% vs. 6.3% (incidence) •
Slide 12: Plinabulin's Regulatory Strategy for CIN: Superior Profile in a Broad Label
Plinabulin’s Regulatory strategy for CIN: Superior Profile in a Broad Label - NDA Accepted by FDA with Priority Review (PDUFA date 11/30/2021) Plinabulin shown to statistically reduce Grade 4 neutropenia in 6 clinical trials (1,200+ patients) Registration Study Supporting Studies Supporting Studies
Slide 13: Neutropenia Vulnerability Gap
Neutropenia Vulnerability Gap Only plinabulin can cover the NVG – day 1 to day 10 – with the potential to elevate the standard of care in CIN Plinabulin’s The plinabulin combo: the perfect pairing to improve protection for patients & Commercial Plan provide greater control for oncologists is purpose
Slide 14: Dr. Ramon Mohanlal: Oncology Development Strategy
Dr. Ramon Mohanlal, CMO and EVP R&D Oncology Development Strategy 14
Slide 15: BeyondSpring Triple IO Combination Strategy with Plinabulin
BeyondSpring Triple IO Combination Strategy with Plinabulin 15
Slide 16: Plinabulin Summary
Plinabulin Summary • Small Molecule Safety Data with plinabulin in >700 – Simple manufacturing process (3-step Synthesis) patients demonstrating a favorable safety and tolerability profile • Given by IV Infusion – Infusion on the same day of the Chemotherapy • MoA: – Primarily through Immune-Enhance
Slide 17: Plinabulin: First-in-Class Agent, Stimulating Innate and Adaptive Immune System
Plinabulin: First-in-Class Agent, Stimulating Innate and Adaptive Immune System (Proven Target: Immune Defense Protein GEF-H1) GEF-H1 activation2 1 Plinabulin Rho/ROCK activation1 Microtubules Neutrophil demargination7 Kill cancer cells4 JNK activation2 Dendritic cell maturation2,3 Tissue level IL-6
Slide 18: Plinabulin Induces Dendritic Cell Maturation in IO Combo
Plinabulin Induces Dendritic Cell Maturation, a Key Step in Initiating Anti-cancer Durable Response in IO Combo ❷ Plinabulin 2 3 ❸ Checkpoint Inhibitors Stimulate maturation of dendritic Optimize T cell response cells to increase antigen presentation Dendritic cells are the most important antigen-pr
Slide 19: 'Hot' and 'Cold' Tumors
‘Hot’ and ‘Cold’ Tumors Cold Tumors Hot Tumors BeyondSpring’s Approach to ‘Cold 'Tumors • Neo-Antigen Generator + Plinabulin + PD1/PD-L1 Inhibitor 19
Slide 20: 'Hot' versus 'Cold'
‘Hot’ versus ‘Cold’ ‘Hot’ Tumors are Immune Responsive – Harbor intrinsically tumor antigens/immunogens capable of stimulating the Immune System – Need something that generates/releases these antigens/immunogens o That ‘something’ can be Radiotherapy of Chemotherapy (or Plinabulin) – Today, Checkpoi
Slide 21: BeyondSpring Approach to 'Hot' Tumors
BeyondSpring Approach to ‘Hot’ Tumors 1. Combination Plinabulin +Radiotherapy+ PD1/PD-L1 • Triple Combination in collaboration with MD Anderson, currently in Phase 1 2. Combination Plinabulin +Chemotherapy+ PD1/PD-L1 • In preparation 3. Combination Plinabulin +PD1/PD-L1 Inhibitor+CTLA-4 Inhibitor •
Slide 22: Plinabulin as a 'Universal' Add-On in Cancer Therapy
Plinabulin as a ‘Universal’ Add-On in Cancer Therapy Plinabulin has the potential to add to Survival Benefit, but also prevents CIN and IR-AEs • In combination with PD1/PD-L1 inhibitor + Chemotherapy : • Survival benefit • Less CIN • Less IR-AEs • In combination with Nivolumab + Ipilimumab • Surviva
Slide 23: Immune-Related AEs (IR-AEs)
Immune-Related AEs (IR-AEs) • CIN is the most prevalent and rate-limiting toxicity for Chemotherapy • The CIN equivalent for IO therapy is IR-AEs • In particular with IO/IO combinations such as • Nivolumab/Ipilimumab • Durvalumab/Tremelimumab • Grade 3/4 IR-AEs generally lead to permanent discontinu
Slide 24: Development Strategy
Development Strategy • Randomized two-arm Head-to-Head comparison trials require large sample size per arm in Phase 1/2 (>n=100) to demonstrate PoC • Not cost-effective • The approach we take is reversal of resistance PD1/PD-L1 therapy • We maintain the same PD1/PD-L1 on which the patient’s disease
Slide 25: Current Studies with Plinabulin for the Anti-Cancer Application
Current Studies with Plinabulin for the Anti-Cancer Application 1. DUBLIN-3: Phase 3 • Plinabulin + Docetaxel vs Docetaxel alone in NSCLC 2. Big Ten Triple Combination: Phase 2 • Plinabulin + Nivolumab + Ipilimumab in SCLC 3. MD Anderson Triple Combination: Phase 1 • Plinabulin + PD1/PD-L1 Inhibitor
Slide 26: Big Ten SCLC Study
Dr. Ramon Mohanlal, CMO and EVP R&D Big Ten SCLC Study 26
Slide 27: Phase I trial of plinabulin with nivolumab and ipilimumab in relapsed SCLC
A phase I trial of plinabulin in combination with nivolumab and ipilimumab in patients with relapsed small cell lung cancer (SCLC): Big Ten Cancer Research Consortium (BTCRC-LUN17-127) study Jyoti Malhotra1, Nasser H. Hanna2, Alberto Chiappori3, Lawrence E. Feldman4, Naomi Fujioka5, Igor I. Rybkin6,
Slide 28: Triple I/O Combo Development for Multiple Cancer Indications
Triple I/O Combo Development for Multiple Cancer Indications in PD-1/PD-L1 Failed Patients – Severe Unmet Medical Needs Trial Name / Indication / Target Program Commercial Rights Status Collaborator SCLC Plinabulin + 6 US sites, including Phase 1 completed, Checkpoint naïve and Nivolumab (PD-1) + Ru
Slide 29: Plinabulin + Nivolumab + Ipilimumab in SCLC: Study Design
Plinabulin + Nivolumab + Ipilimumab in SCLC: Study Design Dose-escalation Phase I study 3+3 Design • In patients with extensive-stage SCLC who had progressed on or after prior platinum-based chemotherapy (±PD-1/PD-L1) Primary objective • To determine dose-limiting toxicities (DLT’s) and recommended
Slide 30: Efficacy Analysis
Efficacy Analysis Data cutoff –December 30,2020 PD-1/PD-L1 PD-1/PD-L1 Efficacy therapy naïve resistant Analysis (n= 6) (n=7) Number of 3 (50%) 3 (43%) patients with PR *PR –Partial Response - RESIST 1.1 : At least a 30% decrease in the sum of diameters of target lesions, taking as reference the base
Slide 31: Efficacy Summary
Plinabulin + Nivolumab + Ipilimumab in SCLC: Big Ten ITT Phase 1 Study Overall Response Rate 46% 43% 50% 45% 40% 35% 30% 23% Efficacy Summary 25% 20% 11% 15% 10% 5% 0% Nivolumab Nivolmumab + Plinabulin + Plinabulin + Ipilimumab Nivolumab + Nivolumab + Ipilimumab Ipilimumab (CPI resistant) Frequency
Slide 32: Plinabulin in Combination with Nivolumab/Ipilimumab in SCLC
Plinabulin in Combination with Nivolumab/Ipilimumab in SCLC Data Conclusion High response rate to previous Immune system re-sensitized CPI failures (43%) Improved Anti-cancer Response Increased antigen presentation (46% ORR vs. 12-23% CPI) simulates T cell activation Durable response (1 pt on combo
Slide 33: MD Anderson Triple Combination
Dr. Steven Lin MD Anderson Triple Combination 33
Slide 34: Common Rule Townhall
Common Rule Townhall 2020-0296: An Open-label, Single-center, Phase 1b/2 Study to Evaluate the Safety of Plinabulin in Combination with Radiation/Immunotherapy in Patients with Select Advanced Malignancies after progression on PD-1 or PD-L1 Targeted Antibodies PI: Vivek Subbiah, MD, Investigational
Slide 35: Interplay of cytotoxic agents with DC maturation
MD Anderson 2020-0296 Plinabulin RT Trial Interplay of cytotoxic agents with DC maturation Zackary B and Efstathiou J, Bladder Cancer 2015
Slide 36: Does plinabulin with RT enhance the anti-tumor immune response?
MD Anderson 2020-0296 Plinabulin RT Trial Does plinabulin with RT enhance the anti-tumor immune response? • What is the proper sequencing of plinabulin and RT? • For radiation sensitization, the sequencing of Drug RT is important since loading the tumor cells ahead of RT would help sensitize the c
Slide 37: Optimal Sequencing of IR with Plinabulin to elicit DC activation
MD Anderson 2020-0296 Plinabulin RT Trial Optimal Sequencing of IR with Plinabulin to elicit DC activation
Slide 38: Plinabulin + RT enhances T-cell proliferation in mixed lymphocyte reaction
MD Anderson 2020-0296 Plinabulin RT Trial Plinabulin + RT enhances T-cell proliferation in mixed lymphocyte reaction
Slide 39: T-cell co-stimulatory molecules besides CD80/86
MD Anderson 2020-0296 Plinabulin RT Trial T-cell co-stimulatory molecules besides CD80/86 1. MHC-1 complex -provides the primary signal for T cell activation 2. ICAM-1- Cell adhesion molecule helps increase the contact between APC and T cells thus increasing APC mediated T cell proliferation 3. CD40
Slide 40: Plinabulin increases PD-L1 along with co-stimulatory molecules
MD Anderson 2020-0296 Plinabulin RT Trial Preliminary results: Plinabulin increase PD-L1 along with co-stimulatory molecules, some augmented by RT Plinabulin=1 µM RT = 10 Gy
Slide 41: Human PBMC derived DCs: Plin stimulated CD86
MD Anderson 2020-0296 Plinabulin RT Trial Human PBMC derived DCs: Plin stimulated CD86 Control Plinabulin 1 μM Plinabulin 10 μM 4.4% 12.3% 28.7%
Slide 42: Human PBMC derived DCs: Plin upregulate PD-L1
MD Anderson 2020-0296 Plinabulin RT Trial Human PBMC derived DCs: Plin upregulate PD-L1 Control Plinabulin 1 μM Plinabulin 10 μM 17.0% 26.2% 65.0%
Slide 43: Induced PD-L1 upon DC activation necessitates anti-PD1/L1 blockade
MD Anderson 2020-0296 Plinabulin RT Trial Induced PD-L1 upon DC activation necessitates anti- PD1/L1 blockade anti-PD-1/-L1 Zackary B and Efstathiou J, Bladder Cancer 2015
Slide 44: Triple combo enhances primary tumor control and abscopal responses
MD Anderson 2020-0296 Plinabulin RT Trial Triple combo (IR (8 Gy x 3) with plinabulin and IO) enhances primary tumor control and abscopal responses D1-3
Slide 45: Triple combination enhances local and distant tumor control
MD Anderson 2020-0296 Plinabulin RT Trial Triple combination enhances local and distant tumor control compared to RT+anti-PD-1 Primary tumor Abscopal tumor
Slide 46: Triple combo enhances immune stimulation in primary and abscopal sites
MD Anderson 2020-0296 Plinabulin RT Trial Triple combo enhances immune stimulation in primary and abscopal sites
Slide 47: Working Hypothesis for the clinical trial
MD Anderson 2020-0296 Plinabulin RT Trial Working Hypothesis for the clinical trial Taken together, these results suggest that “RT priming” followed by plinabulin and anti-PD-1/PD-L1 antibodies may have synergistic effect of stimulating the immune response (“Triple Combo” concept)
Slide 48: 2020-0296: Phase 1b/2 study of plinabulin + RT/IO
MD Anderson 2020-0296 Plinabulin RT Trial 2020-0296: Phase 1b/2 study to evaluate safety of adding plinabulin + RT/IO in IO progressing solid tumors Primary objectives: • To assess safety and tolerability combining plinabulin with RT/IO in • To assess ORR Secondary objectives: • To assess disease co
Slide 49: Seven cancer types progressing on immunotherapy
MD Anderson 2020-0296 Plinabulin RT Trial Seven cancer types progressing on immunotherapy • Bladder Cancer • Melanoma • Merkel Cell Cancer • MSI-H Cancers (of any histology) • Non-small cell lung cancer • Small Cell Lung Cancer • Renal Cell Cancer
Slide 50: Schema
MD Anderson 2020-0296 Plinabulin RT Trial Schema Up to 5 lesions could be treated RT* RT (optional) Progression Toxicity Plinabulin Plinabulin Plinabulin Plinabulin Anti-PD1/PD-L1 Anti-PD1/PD-L1 Anti-PD1/PD-L1 Anti-PD1/PD-L1 Cycle 1 Cycle 2 Cycle 3 Cycle N * RT = 24 Gy/3 fx; 50 Gy/4 fx; 20 Gy/5 fx
Slide 51: Inclusion criteria
MD Anderson 2020-0296 Plinabulin RT Trial Inclusion criteria • Seven histologically or cytologically confirmed neoplasms that progressed on previous immunotherapies (anti-PD-1/PD-L1 +/- chemo or anti-CTLA4) • At least one lesion is amendable for radiation • At least one additional non-contiguous les
Slide 52: Treatment protocol
MD Anderson 2020-0296 Plinabulin RT Trial Treatment protocol All patients will receive RT (3-5 fractions) + plinabulin + anti-PD-1/PD-L1 (cycle 1) plinabulin + anti-PD-1/PD-L1 mAb (cycle 2 and beyond until progression) An optional sequential RT to other untreated lesions at the discretion of the t
Slide 53: Plinabulin dosing
MD Anderson 2020-0296 Plinabulin RT Trial Plinabulin dosing Starting dose of plinabulin at 30 mg/m2 IV on Day 1 and 4 in cycle 1 at the first day of radiation and the end of radiation • If plinabulin is too toxic at 30 mg/m2, then option to go to 20 mg/m2 will be explored Plinabulin is dosed 3-6 hou
Slide 54: Statistical considerations
MD Anderson 2020-0296 Plinabulin RT Trial Statistical considerations Bayesian optimal interval (BOIN) design to find MTD on all comers Two dose levels of 20 mg/m2 and 30 mg/m2, with 30 mg/m2 at the starting level, by starting in cohorts of 3 Once MTD is determined up to 12 pts of all histologies, th
Slide 55: Phase 2
MD Anderson 2020-0296 Plinabulin RT Trial Phase 2 The histology and randomized design will be determined, for up to 102 pts randomized for the two arms A maximum of 184 pts for this phase Ib/2 study
Slide 56: Translational studies
MD Anderson 2020-0296 Plinabulin RT Trial Translational studies Tumor biopsy at pre-dose (<2 wks before RT) and post-dose (at 4th week for Q4wk or 6th week for Q3wk PD-1/PD-L1 regimen) • TCR sequencing • Single cell RNA sequencing Whole blood samples at baseline and every 2 cycles: • Immune profilin
Slide 57: Trial status
MD Anderson 2020-0296 Plinabulin RT Trial Trial status • Activated April 15, 2021 • Consented 5 pts (4 NSCLC, 1 RCC) • 2 had received the first cycle of triple combination therapy without SAEs
Slide 58: Study-101 and DUBLIN-3
Study-101 and DUBLIN-3 Trevor Feinstein MD 58 58
Slide 59: Treatment of advanced NSCLC, without a driver mutation
Treatment of advanced NSCLC, without a driver mutation PD-L1 expression positive > 50% • Pembrolizumab or another checkpoint inhibitor • Platinum + pemetrexed + pembolizumab • Adenocarcinoma Less commonly used • Large cell • Carboplatin + paclitaxel + bevacizumab and atezolizumab Advanced • Not othe
Slide 60: NSCLC
NSCLC Mortality from NSCLC is declining as a result of reduced incidence and survival- extending treatments in some regions, lung cancer remains a leading cause of cancer death worldwide. 1-3 Low survival rates for lung cancer are reflective of the large percentage of patients diagnosed with met
Slide 61: Progression after a platinum chemotherapy and immunotherapy
Progression after a platinum chemotherapy and immunotherapy • Non-squamous histology – Pemetrexed or docetaxel – Docetaxel plus ramucirumab • Squamous histology – Docetaxel +/- ramucirumab 61
Slide 62: Docetaxel as standard of care after platinum progression
Docetaxel as standard of care after platinum progression • Prospective randomized trial of docetaxel versus best supportive care • Performance statuses of 0 to 2 • Excluded with prior treatment of paclitaxel • Randomized to docetaxel 100 mg/m2 (49 patients) or 75 mg/m2 (55 patients) or best supporti
Slide 63: REVEL: Ramucirumab plus docetaxel
REVEL: A randomized phase III trial of Ramucirumab plus docetaxel • Ramucirumab, a recombinant human immunoglobulin G1 monoclonal antibody inhibiting vascular endothelial growth factor receptor-2 • 1253 patients with NSCLC were randomized to receive ramucirumab (10 mg/kg; n = 628) plus docetaxel (75
Slide 64: Heat map mean OS times, second-line NSCLC
“Heat map” mean OS times for non-squamous, EGFR Mutation negative, PD-L1 < 5%, after first-line treatment Colors represent a “heat map” with blues representing large negative differences, increasing through to dark reds for large positive mean differences Vickers, A.D., Winfree, K.B., Cuyun Carter,
Slide 65: 21st century treatment for NSCLC
21st century treatment for NSCLC • In 1999, docetaxel was approved by the FDA for second line NSCLC • Sadly, we have not made improvement • We need treatment with improved: – Survival – Safety – Quality of life 65
Slide 66: Study 101 - Phase 1/2 Study of NPI-2358 + Docetaxel in NSCLC
Study 101 - Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer • Inclusion Criteria: • ECOG performance status ≤ 1 • Pathologically or histologically confirmed advanced non-small cell lung cancer that has progressed after treatment
Slide 67: Study 101 - Outcome Measures
Study 101 - Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer • Primary Outcome Measures : Compare overall survival of patients treated with docetaxel to patients treated with docetaxel + NPI-2358 • Secondary endpoints were safety
Slide 68: Study 101
Study 101 • The 30 mg/m2 Plin cohort was more effective than the 20 mg/m2 cohort as an anticancer agent. • Post hoc exploratory analyses were performed on phase 2 portion in the 30 mg/m2 cohort, n=50 patients received 30 mg/m2 Plin+ D and n=55 patients received D alone. 72% had measurable lung lesio
Slide 69: Phase 2 Study 101: Plinabulin has Anticancer Activity in NSCLC
Phase 2 Study 101: Plinabulin has Anticancer Activity in NSCLC • Plinabulin MoA- targeted patients: Measurable lung lesion with RECIST 1.1 (CT scan > 1 cm in lung), which is around 70% of NSCLC • Improved QoL and favorable Safety profile 69
Slide 70: Plinabulin has Superior Grade Chemotherapy Induced Neutropenia Prevention
Study 101 Phase 2: Plinabulin has Superior Grade 4 Chemotherapy Induced Neutropenia Prevention vs ‘Placebo’ Incidence of neutropenia in patients treated with Docetaxel vs. Docetaxel + Plinabulin-20 mg/m2 35.0% 30.0% 28.8% Percent of patients (%) 25.0% 20.0% 15.0% 10.0% 5.00% 5.0% 0.0% Docetaxel (n=7
Slide 71: Plinabulin appeared to protect against docetaxel-induced neutropenia
Plinabulin appeared to protect against the development of docetaxel- induced neutropenia • Reduced rates of sepsis (3.6% vs 0%, respectively) • Severe infections (3.6% vs 0%, respectively) • Docetaxel dose reductions due to toxicity (19.2% vs 6.7%, respectively) 71
Slide 72: Docetaxel + Plinabulin vs Docetaxel + Placebo in Advanced NSCLC (DUBLIN-3)
Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (DUBLIN-3) Global, single-blinded (blinding for patients only) Stratified for region (Asia/non-Asia), and receiving 2nd- or 3rd-line systemic therapy with Docetaxel + Plinabulin or Docetaxel in a 1:1 ratio docetax
Slide 73: DUBLIN-3 (Study 103): Phase 3 in 2nd/3rd NSCLC
DUBLIN-3 (Study 103): Phase 3 in 2nd/3rd NSCLC, EGFR Wild Type Design EGFR wild-type NSCLC (Pre-specified MOA target patients: Measurable lung lesion) • Plinabulin + docetaxel vs docetaxel, 1:1 randomization, n=559 (fully enrolled) • Approval possible with a single, qualified study • Final analysis:
Slide 74: Study Design
Study Design • Plinabulin 30 mg/m2 administered on Day 1 and Day 8 of each Cycle • Docetaxel 75 mg/m2 is administered on Day 1 of each Cycle 74
Slide 75: Case Study 1
Case Study 1 • 75 year old male smoker, 1.5 packs/day x 50 years with a history of severe mitral regurgitation • January 8, 2015 PET/CT scan: 15 x 10 mm right middle lobe lung mass with hypermetabolic right hilar mediastinal in the left level IV cervical lymphadenopathy • January 14, 2015 left cervi
Slide 76: Case Study 1 imaging
Case Study 1 Before treatment After 13 cycles 76
Slide 77: Case Study 2
Case Study 2 • 78 year old male with history of tobacco abuse and recurrent non-small cell lung cancer, squamous cell histology. He had a past medical history of GERD • 09/24/16 robotic assisted right thoracotomy, right upper lobectomy converted to pneumonectomy and mediastinal lymph node dissection
Slide 78: Case 2 imaging
Case 2 10/20/2017 05/29/2018 78
Slide 79: Supportive Data from CIN STUDY 105 in NSCLC
Supportive Data from CIN STUDY 105 in NSCLC 79
Slide 80: Efficacy of Plinabulin vs Pegfilgrastim in Adults with NSCLC
Efficacy of Plinabulin vs Pegfilgrastim in Adults with Non–Small Cell Lung Cancer • Study BPI-2358-105 (NCT03102606): Phase 2/3, Multicenter, Randomized, Double Blind Study to Evaluate Duration of Severe Neutropenia with Plinabulin Versus Pegfilgrastim in Patients with Solid Tumors Receiving Docetax
Slide 81: Less Thrombocytopenia with Plinabulin vs Pegfilgrastim
Less Thrombocytopenia with Plinabulin in comparison to Pegfilgrastim • Platelet counts by day during treatment cycle 1 expressed as percentage change from baseline • No patients treated with plinabulin had thrombocytopenia of any grade, but 35% of patients treated with pegfilgrastim had at least gra
Slide 82: Less Neutropenia with Plinabulin vs Pegfilgrastim
Less Neutropenia with Plinabulin in comparison to Pegfilgrastim • In another phase 2 study of docetaxel for patients with NSCLC, patients were treated with plinabulin vs Percentage of treated patients against maximum docetaxel alone. neutrophil toxicity grade during treatment cycle 1 • Grade 4 day 8
Slide 83: Less Bone pain with Plinabulin vs Pegfilgrastim
Less Bone pain with Plinabulin in comparison to Pegfilgrastim • Bone pain is a known toxicity to Pegfilgrastim • In patients who had no bone pain at study entry • Plinabulin treated patient had no bone pain after day 3 • 35% of patients treated with pegfilgrastim reported bone pain • Pegfilgrastim p
Slide 84: Enhanced Quality of life with Plinabulin vs Pegfilgrastim
Enhanced Quality of life with Plinabulin in comparison to Pegfilgrastim • Plinabulin 20 mg/m2 showed a significant improvement in global health status (P < .001) vs pegfilgrastim • Compared with their baseline state, patients treated with plinabulin 20mg/m2 significantly benefited in fatigue (P = .0
Slide 85: Target Product Profile
Target Product Profile Current Standard of Care Plinabulin - Docetaxel Combination • Potential survival benefit, with more • Modest survival benefit long survivals due to GEF-H1 IO MOA • Potential superior safety profile, • Severe safety concerns, e.g. CIN including CIN reduction • Poor Quality of L
Slide 86: Elizabeth Czerepak, CFO
2438, Eps BeyondSpring PP a Elizabeth Czerepak, CFO 86
Slide 87: BeyondSpring – Value Proposition
BeyondSpring – Value Proposition BeyondSpring Value Proposition Committed to raising the standard of care for cancer patients, in the Late-stage assets – Potential launch of Plinabulin in CIN early 2022 largest global markets, with first-in- – Phase 3 (Dublin-3) data in NSCLC in mid 2021 class treat
Slide 88: Recent Goals Achieved, Near Term Milestones for Value Creation
Recent Goals Achieved, Near Term Milestones for Value Creation Plinabulin: CIN (Targets broad range of cancer and chemotherapy) Value creation in elevating SOC; Plinabulin Life-cycle Management Life cycle management 2022+ Anti-cancer I/O Combo Early Clin. Data NSCLC (with chemo): Q4 2021 • Lar
Slide 89: www.beyondspringpharma.com
www.beyondspringpharma.com 89
Slide 90: Questions? Answers.
Questions? Answers. 90